Fig. 2.

PlGFs do not promote migration of iBREC. Migration of iBREC over 24 h towards fibronectin and VEGF₁₆₅, VEGF₁₂₁, PlGF-1, PlGF-2 or VEGF-E (25 ng/ml each) as single agents or in combination was measured by a modified Boyden Chamber assay in the absence (a) or presence (b) of 60 μg/ml ranibizumab. a VEGF₁₆₅ and viral VEGF-E, but not PlGF-1 or PlGF-2 significantly stimulated migration. b Migration induced by treatment with a mixture of VEGF₁₆₅, VEGF₁₂₁, PlGF-1, and PlGF-2 was strongly inhibited by ranibizumab. GF growth factor mix containing VEGF₁₆₅, VEGF₁₂₁, PlGF-1, and PlGF-2